HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL
Blondin N, Proescholdt C, Kelly J. HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL. Neuro-Oncology 2018, 20: vi119-vi119. PMCID: PMC6217248, DOI: 10.1093/neuonc/noy148.495.Peer-Reviewed Original ResearchQuality-adjusted life yearsHealth utility valuesLong-term survivorsLong-term survivalHealth utilityCondition-specific questionnaireEF-14 trialQuality of lifeHealth economic evaluationsGeneral population sampleStable diseaseAdverse eventsPreference-based measuresMultiple myelomaGBM patientsHealth state scenariosGlioblastoma patientsPatientsGBM treatmentSurvival rateLife yearsNew treatmentsUtility valuesDiagnosisHealth PanelQOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT
Blondin N. QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT. Neuro-Oncology 2018, 20: vi214-vi215. PMCID: PMC6217477, DOI: 10.1093/neuonc/noy148.890.Peer-Reviewed Original ResearchOverall survivalCannabis therapyTherapeutic cannabisPalliative useMedian ageCare treatmentGBM patientsSignificant adverse eventsTime period 2Time period 1Diagnosis dateAdverse eventsPatient ageSurvival benefitTumor characteristicsTherapeutic roleTreatment strategiesPatientsAnimal modelsHuman patientsGlioblastoma treatmentTherapeutic treatmentCannabis useTherapyGlioblastoma